LOS ANGELES - Eli Lilly and Company said on Tuesday that it has delayed enrollment in clinical trials of its antibody treatment for COVID-19 to “ensure the safety of the patients participating in this study” due to a potential safety concern. “Safety is of the utmost importance to Lilly.
We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” a company spokesperson wrote in an email.